<DOC>
	<DOCNO>NCT00026494</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I/II trial study effectiveness temozolomide vinorelbine treat patient recurrent brain metastasis .</brief_summary>
	<brief_title>Temozolomide Vinorelbine Treating Patients With Recurrent Brain Metastases</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose vinorelbine administer combination temozolomide patient recurrent brain metastasis ( phase I accrual complete ) . - Determine safety feasibility treatment regimen patient . - Determine efficacy treatment regimen , term objective radiographic response overall progression-free survival , patient . OUTLINE : This dose-escalation study vinorelbine . Patients receive vinorelbine IV 5-10 minute day 1 8 oral temozolomide daily day 1-7 15-21 . Courses repeat every 28 day 1 year absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos vinorelbine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 6 patient experience dose-limiting toxicity . Once MTD determine , additional 20-35 patient treat dose level . Patients follow every 3-4 month . PROJECTED ACCRUAL : A minimum 3 patient accrued phase I portion study 20-35 patient accrue phase II portion study within 2 year .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>INCLUSION CRITERIAL : Age &gt; = 18 year . Karnofsky performance score &gt; = 60 . Histopathologic confirmation diagnosis solid tumor malignancy . The brain metastasis diagnosis per se pathologically confirm clinical neuro radiographic picture typical . MRI ( CT patient undergo MRI ) evidence evaluable disease brain . Absolute neutrophil count &gt; = 1,500/mm³ . Platelet count &gt; = 100,000/mm³ . Hemoglobin &gt; = 10 g/dl . BUN serum creatinine &lt; 1.5 time upper limit normal . Total direct bilirubin &lt; 1.5 time upper limit normal . SGOT SGPT &lt; = 3 time upper limit normal . Alkaline phosphatase &lt; = 2 time upper limit normal . At least two week must elapse brain biopsy , craniotomy , surgery . Life expectancy &gt; = 8 week . Patient legal guardian legal nextofkin must provide write informed consent prior patient 's registration study . At least four week must elapse previous external beam radiation therapy , eight week stereotactic radiosurgery . Patients treat radiosurgery evidence progression distant site brain , confirmation tumor progression biopsy PET scan . EXCLUSION CRITERIA : Previous treatment temozolomide , dacarbazine vinorelbine . Patients recover acute toxicity prior therapy . Patients evidence leptomeningeal metastasis primary dural metastasis . Patients poor medical risk nonmalignant systemic disease , well acute infection require treatment intravenous antibiotic . Patients whose psychiatric condition would , judgment principal investigator , make unlikely could adhere requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>tumor metastatic brain</keyword>
</DOC>